
Medpace rose 7.1% from $592.18 to $633.98, behind the S&P 500's +8.0%. Its worst day was Apr 23 (−22.6%), and its low came Apr 23 at $393.42.
Nov 19, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $4.67 beat the $4.21 estimate on $708.5M revenue (est. $687.0M); FY revenue guidance of $2.8B–$2.9B against the $2.7B consensus.
−15.9% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Medpace shares fell 7.1%, while the S&P 500 fell 1.5%.
−7.1% · S&P 500 −1.5%
EPS of $4.28 beat the $3.87 estimate on $706.6M revenue (est. $696.3M); FY revenue guidance of $2.8B–$2.9B against the $2.8B consensus.
−22.6%, the year's worst day, on 2M shares, the year's heaviest volume · S&P 500 −0.4%
Medpace shares rose 8.3%, while the S&P 500 fell 0.0%.
+8.3% · S&P 500 0.0%
EPS of $4.25 beat the $3.99 estimate on $707.3M revenue (est. $687.8M); FY revenue guidance of $2.8B–$2.9B against the $2.8B consensus.
+14.7%, the year's best day · S&P 500 −1.2%
EPS of $4.84 beat the $4.46 estimate on $716.0M revenue (est. $713.3M); FY revenue guidance of $2.8B–$2.9B against the $2.8B consensus.
−1.3% · S&P 500 −1.2%
Where it ended: a close of $633.98 on Nov 19, 2026. Up next: Q4 2026 earnings on Feb 8, 2027 (EPS est. $4.86, revenue est. $717.9M).
Nothing in the past 12 months.
All MEDP dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MEDP and SPY from Benzinga historical bars. Not investment advice.